Alembic Pharmaceuticals Ltd

APLLTD

Watchlist

AI Mode

‌

Market Cap

₹ 16,998 Cr

P/E

26.80

‌

Investment Checklist

How to read checklist?

Performance

UNDER PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

LOW MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Alembic Pharmaceuticals Limited is a global manufacturer and marketer of generic pharmaceutical products. The company reported a 16% year-over-year revenue growth for Q2 FY26, driven by a strong performance in international markets including the US and Ex-US generics.

Alembic's US generics business grew 21% YoY, supported by key product launches and market share gains, underscoring its strategic focus on expanding its footprint in the US pharmaceutical market.

The Ex-US generics business saw an impressive 31% YoY growth, driven by targeted execution and strong customer demand across key markets including Europe and Canada.

The company's acquisition of Utility Therapeutics marks its entry into the US branded market, highlighting its strategic intent to tap into new revenue streams through mergers and acquisitions.

Alembic's R&D investment represents 10% of its revenue, reflecting a strong commitment to building a pipeline of high-value products, especially in complex and specialty divisions.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

Market Cap

16,998 Cr

Volatility

Low Risk

P/E Ratio

26.8

Industry P/E

27.8

PEG Ratio

1.5

P/B Ratio

3.2

52W High

1,122.40

52W Low

725.60

Sales CAGR

7.12%

6.21%

7.86%

10Y

8.04%

Profit CAGR

-5.49%

-2.54%

-12.29%

10Y

-3.58%

ROE

TTM

11.93%

10.72%

13.00%

10Y

16.96%

ROCE

TTM

12.59%

12.61%

15.18%

10Y

19.43%

Technicals

‌

Forecasts

No. of Analysts

16

1Y Price Target

1055.95 ▲ 24.85%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AUROPHARMA	1185.50	68,854 Cr	20.12	1.96	0.00	9.77	12.69	6.51
ALKEM	5620.35	67,152 Cr	28.57	5.03	0.80	17.69	18.13	11.89
GLENMARK	1986.05	56,027 Cr	22.28	5.85	0.13	26.24	30.84	5.31
LAURUSLABS	1004.30	54,218 Cr	79.27	11.28	0.12	14.23	15.05	7.21
IPCALAB	1440.55	36,570 Cr	36.94	4.92	0.28	13.33	17.89	7.02
PPLPHARMA	171.70	22,823 Cr	—	2.83	0.08	-0.29	4.50	-0.15
APLLTD	863.50	16,998 Cr	26.80	3.20	1.27	11.93	12.59	7.52

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	1,486	1,595	1,631	1,517	1,562	1,648	1,693	1,770	1,711	1,910
Expenses	1,287	1,387	1,364	1,257	1,325	1,409	1,433	1,498	1,429	1,594
Operating Profit	199	208	266	260	237	239	260	272	281	316
OPM %	13.37	13.06	16.34	17.14	15.16	14.52	15.37	15.37	16.45	16.53
Other Income	12	9.64	2.84	3.21	2.42	30	9.86	14	6.05	8.33
Interest	14	16	15	11	13	19	22	25	24	24
Depreciation	66	68	69	69	69	71	70	69	74	76
Profit Before Tax	130	135	185	183	157	180	178	192	190	224
Tax %	7.06	-1.43	2.24	2.54	14.32	15.12	22.54	18.40	19.19	17.88
Net Profit	121	137	180	178	135	153	138	157	154	184
EPS in Rs	6.14	6.95	9.23	8.48	6.84	7.79	7.01	7.98	7.85	9.40

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	3,135	3,131	3,935	4,606	5,393	5,306	5,653	6,229	6,672	6,821
Expenses	2,519	2,488	3,061	3,383	3,913	4,432	4,944	5,295	5,664	5,768
Operating Profit	615	643	874	1,223	1,480	874	708	933	1,008	1,053
OPM %	19.63	20.54	22.20	26.55	27.45	16.48	12.53	14.98	15.11	15.43
Other Income	2.02	7.03	9.38	-39	87	56	-28	27	56	60
Interest	5.23	3.40	18	27	16	18	50	56	79	89
Depreciation	83	105	115	157	183	287	275	273	279	283
Profit Before Tax	529	541	749	1,000	1,368	625	355	632	707	740
Tax %	23.09	22.24	20.92	19.92	18.52	16.70	3.55	2.53	17.70	18.80
Net Profit	407	421	593	801	1,115	521	342	616	582	601
EPS in Rs	20.51	21.00	29.73	42.17	60.21	26.56	17.39	30.80	29.62	32.24
Dividend Payout %	18.70	18.27	17.74	22.74	23.66	37.74	45.98	35.11	37.06	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	38	38	38	38	38	39	39	39	39	39
Reserves	1,560	1,865	2,182	2,681	3,182	5,028	5,198	4,331	4,779	5,152
Borrowings	114	89	708	928	1,747	584	717	722	513	1,258
Other Liabilities	718	698	1,013	1,131	1,022	1,058	1,167	1,090	1,114	1,324
Total Liabilities	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446	7,773
Fixed Assets	708	799	993	1,158	1,552	1,788	1,798	2,398	2,547	2,524
CWIP	93	396	1,010	1,551	1,846	2,183	2,304	601	524	837
Investments	53	50	42	49	18	236	118	96	93	127
Other Assets	1,575	1,444	1,896	2,019	2,573	2,502	2,902	3,087	3,281	4,285
Total Assets	2,429	2,689	3,941	4,778	5,989	6,709	7,122	6,183	6,446	7,773

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	948	329	312	812	449	1,463	552	724	803	88
Cash from Investing Activity	-307	-486	-884	-756	-732	-839	-372	-448	-321	-568
Cash from Financing Activity	-224	-129	503	59	155	-597	-217	-262	-438	444
Net Cash Flow	417	-286	-69	115	-128	27	-37	14	45	-37

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.61%	69.67%	69.67%	69.74%
FIIs	4.99%	4.55%	4.34%	4.50%	4.52%	4.46%	4.32%	3.94%	4.17%	3.94%	3.96%	4.05%
DIIs	12.76%	13.31%	13.65%	14.22%	14.50%	15.39%	15.47%	16.06%	16.06%	16.43%	16.46%	16.30%
Public	12.65%	12.53%	12.40%	11.67%	11.37%	10.54%	10.60%	10.39%	10.16%	9.96%	9.90%	9.92%
Total Shareholders	1,01,864	99,522	97,607	89,552	85,212	76,567	74,829	91,429	93,944	91,336	89,013	89,969

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Oct 01, 2025	Nirayu private limited	Insider - Promoter Group	Acquisition	903.55	0.90 Cr	10,000	0.00
Sep 29, 2025	Chirayu ramanbhai amin huf	Insider - Promoter Group	Acquisition	925.37	1.39 Cr	15,000	0.00
Sep 29, 2025	Nirayu private limited	Insider - Promoter Group	Acquisition	901.78	0.45 Cr	5,000	0.00
Sep 17, 2025	Chirayu ramanbhai amin huf	Insider - Promoter Group	Acquisition	962.23	0.50 Cr	5,200	0.00
Sep 11, 2025	Chirayu ramanbhai amin huf re...	Insider - Promoter Group	Acquisition	959.34	2.40 Cr	25,000	0.01
Sep 09, 2025	Chirayu ramanbhai amin huf	Insider - Promoter Group	Acquisition	948.05	1.90 Cr	20,000	0.01
Sep 05, 2025	Chirayu ramanbhai amin huf	Insider - Promoter Group	Acquisition	963.49	1.26 Cr	13,068	0.00
Sep 03, 2025	Chirayu ramanbhai amin huf	Insider - Promoter Group	Acquisition	955.98	1.91 Cr	20,000	0.01
Sep 03, 2025	Chirayu ramanbhai amin huf	Insider - Promoter Group	Acquisition	941.25	1.25 Cr	13,290	0.00
Mar 28, 2025	Nirayu limited	Insider - Promoter Group	Acquisition	905.13	1.15 Cr	12,665	0.00

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Regulatory Filing

2 hours ago

Disclosure of Litigation Against MGVCL

Alembic Pharmaceuticals has disclosed in a regulatory filing that it is contesting supplementary invoices from MGVCL related to a rooftop solar PV system installation through a writ petition.

Regulatory Filing

1 day ago

Special Window for Re-lodgement of Physical Shares

Alembic Pharmaceuticals has announced a special window from July 7, 2025, to January 6, 2026, for re-lodgement of transfer requests of physical shares.

Regulatory Filing

4 days ago

Loss of Equity Share Certificate Notice

Alembic Pharmaceuticals Limited published a notice in Business Standard regarding the loss of an equity share certificate and the process to claim duplicate shares.

Press Release

5 days ago

USFDA Approval for Loteprednol Etabonate and Tobramycin

Alembic Pharmaceuticals Limited has received final approval from the USFDA for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, indicating a significant milestone for the company.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Showing 1 - 8 of 17

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

Alembic's US generics business grew 21% YoY, supported by key product launches and market share gains, underscoring its strategic focus on expanding its footprint in the US pharmaceutical market.

The Ex-US generics business saw an impressive 31% YoY growth, driven by targeted execution and strong customer demand across key markets including Europe and Canada.

The company's acquisition of Utility Therapeutics marks its entry into the US branded market, highlighting its strategic intent to tap into new revenue streams through mergers and acquisitions.

Alembic's R&D investment represents 10% of its revenue, reflecting a strong commitment to building a pipeline of high-value products, especially in complex and specialty divisions.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

Market Cap

16,998 Cr

Volatility

Low Risk

P/E Ratio

26.8

Industry P/E

27.8

PEG Ratio

1.5

P/B Ratio

3.2

52W High

1,122.40

52W Low

725.60

Sales CAGR

7.12%

6.21%

7.86%

10Y

8.04%

Profit CAGR

-5.49%

-2.54%

-12.29%

10Y

-3.58%

ROE

TTM

11.93%

10.72%

13.00%

10Y

16.96%

ROCE

TTM

12.59%

12.61%

15.18%

10Y

19.43%